Anti-VHL Rabbit Polyclonal Antibody

Supplier: Pierce Biotechnology

PA513487
CAPIPA5-13487EA 2801.79 CAD
CAPIPA5-13487
Anti-VHL Rabbit Polyclonal Antibody
Antibodies
This antibody is predicted to react with rat based on sequence homology. Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

Recommended Dilutions: Western Blot: 1:1000, Immunofluorescence: 1:10-1:50, Immunocytochemistry: 1:10-1:50, Immunohistochemistry: 1:10-1:50, Flow Cytometry: 1:10-1:50

Type: Primary
Antigen: VHL (von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase)
Clonality: polyclonal
Clone:
Conjugation: unconjugated
Epitope:
Host: Rabbit
Isotype: none
Reactivity: Human
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR